ThromboGenics says FDA accepts Ocriplasmin filing

BRUSSELS (Reuters) – Drug developer ThromboGenics NV said on Tuesday that U.S. regulators have accepted its request for approval of its main drug, and granted it priority status, meaning it could be ready for sale in six months. ThromboGenics licensed the eye drug ocriplasmin in March to Novartis’s opthalmic division to sell outside the United States, but it plans to market the product itself in the U.S. (Reporting By Ben Deighton; editing by Justyna Pawlak)

Ampio shares rise on bullish online report

(Reuters) – Shares of Ampio Pharmaceuticals Inc rose as much as 39 percent on Friday after an investment website said it expects Ampio to be the next “blockbuster” stock. With 3 blockbuster drugs, Ampio is all primed up for loads of news about clinical trials, the FDA and potential partners, Seeking Alpha said in a report published on Friday. Ampio’s drug to treat premature ejaculation is in a late-stage study, while its diabetes related eye disease and anti-inflammation drugs have completed mid-stage trials. …

FDA says Covidien device can get stuck in brain

WASHINGTON (Reuters) – A Covidien Plc device for rare malformed blood vessels can get stuck in the brain and has been linked to nine patient deaths, U.S. regulators warned. The device, made by Covidien unit ev3, uses a spongy material to block off blood flow to abnormal tangles of blood vessels before they are removed by surgery. The material is delivered to the brain through a tube inserted into a groin artery, known as a catheter. But the catheter can get stuck in the spongy material while inside the brain, causing serious complications including hemorrhage and death, the U.S. …

1 5 6 7 8 9 19